Clinical Trial Update: Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating idarubicin, cytarabine, and gemtuzumab ozogamicin in patients with previously untreated high-risk myelodysplastic sy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)
• Idarubicin (idarubicin)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED